EPRX Company Profile and Key Details

EPRX has shown sold momentum, gaining 10.0% over the past week and 56.06% over the past quarter, though year-to-date performance is up 19.47%. Short-term trend indicators are bearishly aligned (SMA20 -1.9%, SMA50 1.85%, SMA200 36.33%). The stock’s 14-day RSI is 48.91 (neutral), while the ATR of 0.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -12.23% below its high and over 205.21% above its low. Average 10-day trading volume of 224.76 thousand shares is in line with the 3-month average of 205.11 thousand, indicating normal recent market interest.

Eupraxia Pharmaceuticals Inc. generated EPS of -$0.87 over the past year. Five-year average earnings growth is -12.32%. Wall Street analysts project EPS growth of 11.64% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $19.00 to $9.00. The high target offers 142.97% upside. The low target suggests 15.09% downside. The mean target is $12.50. This offers 59.85% upside. Eupraxia Pharmaceuticals Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 04, 2025, missed forecasts by -17.39%. The prior quarter beat by 23.81%. Over the last six quarters, Apple has recorded several small beats. These include 0.37% in August 07, 2024.

Eupraxia Pharmaceuticals Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.72. This means the shares are trading above this model’s fair value.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) closed at $7.74 USD, losing -$0.08 (-1.02%) from the previous close of $7.82. The stock is currently mid-range between its 52-week high and low $2.68 and $9.32. With a market capitalization of about $259.14 million, Eupraxia Pharmaceuticals Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.38). Key stats such as the average daily volume over the past year has been around 211.79 thousand shares, volume is running light vs its 52-week average. Headquartered in Victoria, BC, Eupraxia Pharmaceuticals Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO James A. Helliwell, the company employs approximately 33 people and listed since April 05, 2024. Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector.

Our AI price prediction model suggests that Eupraxia Pharmaceuticals Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.07%, with price expected at $7.58 by March 23, 2026, within a range of $7.30 to $7.86 3-Month Outlook: Projected fall of -22.38%, reaching $6.07 by June 05, 2026, with a range of $5.85 to $6.26. 1-Year Outlook: Projected gain of 84.14%, with price at $14.40 by March 09, 2027, within a range of $2.73 to $22.14.

Eupraxia Pharmaceuticals Inc. trades at a P/E ratio of -8.5, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.79 suggesting the stock is closer to book value. The P/FCF stands at -13.87, also below market averages.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) shares are up 19.47% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Eupraxia Pharmaceuticals Inc. trading at a premium to the broader market with a P/E of -8.5. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $12.50, suggesting 59.85% upside. Our AI forecast model points to short-term weakness (-3.07% over two weeks), a medium-term fall (-22.38% over three months), and a longer-term gain (84.14% over one year), with expected trading ranges indicating moderate volatility.